Combination treatment for advanced stomach cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a new combination of drugs for advanced stomach cancer that has not been treated before. The goal is to see if adding a cholesterol-lowering drug to standard chemotherapy and immunotherapy can help shrink tumors and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have advanced stomach or gastroesophageal junction cancer that cannot be removed with surgery.
- Your cancer must be a specific type called pMMR/MSS, which your doctor can check.
- You must not have had any prior treatment for this cancer (like chemotherapy or radiation).
- You must be generally healthy, able to perform daily activities, and have adequate organ function.
- You must not have certain infections (like HIV, active hepatitis B or C, or tuberculosis) or autoimmune diseases.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs (one targeted therapy and one immunotherapy) given with chemotherapy before and after surgery for stomach cancer that hasn't spread far. The goal is to see if this approach can improve outcomes for people with locally advanced disease.
This trial tests a new combination of drugs for advanced stomach cancer that has spread or come back. It aims to see if adding an immune therapy and a bacterial extract to standard chemotherapy can help control the cancer better.
This clinical trial is testing a combination of two immunotherapy drugs (AK104 and AK112) plus chemotherapy as the first treatment for advanced stomach or gastroesophageal junction cancer. It aims to see if this combination helps control the cancer better than standard therapy.
This trial tests a combination of immune therapy and chemotherapy given before surgery for stomach or esophagus-stomach cancer. The goal is to shrink the tumor to make surgery more effective and possibly improve outcomes.
This trial tests a combination of an immunotherapy drug (sintilimab) and two chemotherapy drugs (nab-paclitaxel and tegafur) as a first treatment for stomach or gastroesophageal junction cancer that cannot be removed by surgery or has spread. The goal is to see if this combination helps people live longer and controls the cancer better.
This trial tests a new combination of drugs (RC48, sintilimab, and SOX chemotherapy) for people with stomach or gastroesophageal junction cancer that cannot be removed by surgery, has not been treated before, and has a specific HER2 score (1+ or 2+). The goal is to shrink the tumor enough to possibly allow surgical removal.
Hear when a new Gastric Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.